

Raffles PharmaTech Company Overview

(May 2017)



莱佛士制药技术有限公司

Raffles PharmaTech Pte Ltd

About Us

- Established in August 2011 with a foundation in innovative organo-catalysts. Raffles expanded into a comprehensive and product and service provider for pharmaceutical industry.
- Utilizing our experience within major global pharmaceutical companies, we develop and manufacture small molecule key raw materials, specialty reagents, intermediates and APIs for the pharmaceutical industry.

What we Have

Small molecule R&D and manufacturing capabilities and facilities

Who we Serve

Pharma Companies

CMOs

What we Deliver

- Development of API stages
- Intermediates
- Specialty materials and reagents

- Difficult to Source Materials
- Specialty materials and reagents

Staff Composition

Total 67 people: PhD(6), MSc (12), BSc(37)

■ R&D (38)

- 30 synthetic chemists (Across 4 Teams)
- 8 analytical development chemists

■ Manufacturing (17)

- 10 Operations (Ops + Production Manager)
- 2 Production Chemists
- 2 QA, 3 QC
- 1 RA
- 2 Purchasing and Logistics

■ Commercial and Supporting (12)

- 6 Sales and business development
- 6 Supporting

■ CEO, Dr Weiping Ye

2003 BSc, Chemistry, Peking University

2003 Minor, Economics, Peking University

2006 PhD, National University of Singapore

2006-2010 GlaxoSmithKline, Senior/Chemist

2008-2010 GlaxoSmithKline, Lead Chemist for NCE Retigabine

2009-2010 **GSK-Singapore Green and Sustainable Manufacture Fund**,
Project Manager, S\$33 millions.

2010-2011 Pfizer, Manager – API Global External Supply Asia

Sept 2011-now, CEO and Co-Founder of Raffles PharmaTech

- Published 10 international paper and filed 14 patents
- Awarded GSK “**Excellence Recognition Award**” 3 times;
- Led/ worked on 8 commercial products and 2 NCE’s were approved
- Managed Pfizer’s strategic API suppliers in Asia with total annual spend of more than US\$200 millions.
- Led the registration of 2 Pfizer API projects in more than 180 countries
- Strong and proven track record of API process development, international project management, and commercialization.



■ VP of BD, Andrew Phillis PhD

2000 BSc, Chemistry University of Waikato, New Zealand

2002 MSc(Hons), University of Waikato, New Zealand

2006 PhD, Australian National University

2007- 2010 GlaxoSmithKline, Chemist (R&D Pilot Plant)

2010- 2011 GSK, Senior Chemist (Commercial Production)

2011- 2012 GSK, Project Manager

2011- Mar 2014 GSK, Senior Process Chemist (2nd Generation API Group)

Apr 2014-June 2016, R&D Director, Raffles PharmaTech

June 2016 – Now: VP of BD



- Led/worked on 9 products, out of which 6 were successfully commercialized;
- Awarded GSK “**Excellence Recognition Award**” 2 times;
- Strong experience in both R&D and commercial product;
- Proven track record in developing green second generation processes that lead to significant cost and environmental benefits

■ Deputy GM, Dr Junye Xu

2003 BSc, Suzhou University

2008 PhD, National University of Singapore

2007-2008 Teaching Assistant, National University of Singapore

2009-2011 Codexis (NSDQ: CDX), Staff Scientist

Sept 2011-now, Co-Founder and Deputy GM of Raffles PharmaTech



- Awarded US “**2012 Presidential Green Chemistry Challenge Award**” for the excellent work on Simvastatin enzymatic process development

- 4 US Patents on enzymatic process development:

US20110111468A1, US20120244582A1, US20130260426A1, US20130130351A1.

- Successful enzymatic process development of more than 8 products, including Simvastatin, Esomerprazole, Armodafinil, etc.

- One successful technology transfer of enzymatic process to a major MNC pharma for commercialization

■ R&D Director, Dr. Tom Zhou

2003 B.Sc. Chemistry, Nankai University

2009 Ph.D. Organic chemistry, Nankai University

2009-2011 Guangdong Hec pharma., group leader

2011-Jan 2016 Lonza, senior chemist

2016-now, R&D Director of Raffles PharmaTech

- Published 5 international papers
- Awarded Lonza “**Operation Excellence Award**” 2 times;
- Widely experiences in pharmacy industry including: development of new drugs, development of generics, contract development and manufacturing business.
- Led more than 20 projects in 7 years work experiences.
- Capable in from mg to 100 tons scales.
- Experienced and innovative.



■ Scientific Advisor, Prof. Choon-Hong Tan

1996 Honors(First Class), National University of Singapore
1999 PhD, Cambridge University
1999-2003 Post-doc, RF, Harvard University
2003-2012 Assoc Professor, National Univ. of Singapore
2012-2015 Associate Professor, Nanyang Technological Univ.
2016-Now Full professor, Nanyang Technological Univ.
2011-now Scientific Advisor, Raffles PharmaTech



- World renowned scientist in organo catalysis
- Published more than 100 international paper and 4 patents.
- Developed series of novel organo catalysts that see wider and wider application in pharmaceutical synthesis.
- Received multiple international awards, such as
 - ❑ Asia Core Program Lectureship Award from Taiwan (2013)
 - ❑ GSK-SNIC Organic Chemistry Award (2011)
 - ❑ Young Chemist Award (2009)
 - ❑ Young Scientist Award (2009)
 - ❑ CRISP award (2009)
 - ❑ UK-Singapore Partners In Science Collaboration Development Awards (2008)

Process Development

Our team has many years of experience in developing and installing synthetic processes for the pharmaceutical industry.

Chemical Synthesis


- The heart of a small molecules business
- Design of Experiments (DoE) for support of screening, optimization and robustness studies.

Our core competencies include:

- Route scouting: Routes selected for safety, quality and cost.
- Optimization: High quality, low cost, and robust.
- Impurity studies: Scope of studies based on of ICH guidelines
- Scale-up and industrialization or Tech-Transfer:
 - Scale-dependence and robustness.
 - PARs established
 - CPPs designated

Catalysts screening services

- Parallel screening and fast-LC analysis
- Biocatalysts (enzymes)
- Organocatalysts
 - Holder of Codexis enzyme screening kits (NSDQ: CDX) in China
 - Codexis is the global leader in enzyme evolution and application in the pharma industry.





www.codexis.com


Analytical Methods Development

- We have analytical labs staffed by highly experienced teams located with our development sites.
- Analytical methods development.
- Method validation for IPM, IPC and product release testing.
- Methods development for chiral products.

- Shenzhen R&D Site: 1800 m²
- 7 labs
 - 4 Synthetic Chemistry
 - 1 Catalyst Screening Lab (Enzymes and organocatalysts)
 - 1 Analytical development
 - 1 IPM/IPC testing



R&D Equipment



Synthetic Chemistry Lab



Kilo-Scale Lab



**Analytical
Development Lab**



QC Testing Lab



Stability Chambers

Analytical Instruments



HPLC
Agilent and Shimadzu




GC/MSGC



Muffle Furnace (ROI)



Polari meter



**Karl Fischer
Titrator**



Melting Point

- Experienced Team from global pharma and contract organizations
- **3 facilities at 2 sites**
 - **Kilo-scale facility:** Dayawan
 - **Pilot plant:** Dayawan
 - **Large scale manufacturing facility:** Mu dan Jiang
- Capacity from grams to tons.
- Robust quality system.
- Full regulatory support is available with CMC documentation
- High quality, occupational health and safety standards
- Certified ISO9001 compliant quality system.

By partnering with us for development and manufacturing, you can stay focused on accelerating your product development, and simplify your supply chain.

Quality and Compliance

- Our commitment to high quality products translates into our services business.
 - Robust process design.
 - Comprehensive analytical testing.
 - ISO9001 certified quality system.
 - Mudan jiang plant is GMP certified
- Physical and chemical definition and analysis
- Impurity tracking
- Stability testing for various ICH recommended climatic zones


Dayawan Site

- 2000 m²
- ISO 9001:2008 Certified
- Kilo scale facility.
 - In operation since Q3 2015
 - 4 x 50L Reactors
 - 50L Double Cone Drier
 - 8 Vacuum Tray Driers
 - 100 L chromatography column
 - 30 L Rotary evaporator
- QC testing
- Stability monitoring
- Product Warehouse



Dayawan Site

- Pilot Scale facility.
 - 2 x 200 L Glass lined reactors
 - 1 x 200 L 316 SS reactor
 - 20kg per cycle centrifuge
 - 100 L Double cone drier
 - Highly Configurable



Dayawan Site

- Environmental protection controls.



Above ground Waste Storage Tanks
Easily inspected and emptied



- Spray scrubber
- Cooling tower
- Fume hood vapour extraction system

Mu Dan Jiang Site


- Raffles is a significant shareholder
- CFDA inspected and approved.
- GMP certified.
- Clean room
- 16 Reactors (50 - 3000 L)
- Purified water system



Future Dayawan Site

- Raffles is planning to secure a block of land ~20,000 m² in 2017.
- Located in Dayawan, near to the current Dayawan site which houses the current pilot facility and kilo scale lab.
- Our vision is to build a world-class, state of the art manufacturing facility for production of advanced intermediates and APIs.
- Targeting to break-ground in mid 2018, and start operations in early 2020.

Locations





- ★ Awarded multiple **Science and Technology Project Grants**
 - **4** from Daya Bay Economic and Technology Development Zone
 - **3** from the Huizhou City
 - **2** from Guangdong Provincial government
 - **2** from Central Government.
- ★ **17** Chinese patent applications (**6 granted**) and **3** PCT international applications (**1 granted**).
- ★ Our Organic Phase Transfer catalyst was awarded “**2012 Guangdong High-Tech Product**” certification.
- ★ Our project on “Novel Asymmetric Phase Transfer Catalyst” (Code: 20134400012) was awarded grant support from the **Chinese State Administration of Foreign Experts Affairs in 2013**.
- ★ Certified as **State High-Tech Enterprise in 2015**.
- ★ Andrew Phillis, PhD awarded, “**Leading Talent**” title from Huizhou Government.

ISO 9001 Certification



Honors and Awards



Academic Partners



Nanyang Technological University



Singapore Polytechnic



South China Normal University



中山大學 惠州研究院

Huizhou Research Institute of Sun Yat-Sen University

**Huizhou Research Institute of
Sun Yat-Sen University**



**Shenzhen Institute of Advanced Technologies,
Chinese Academy of Science**



Henan University



Thank you !

General Enquiries : info@rafflespt.com
Business Enquiries : sales@rafflespt.com
Website : www.rafflespt.com



莱佛士制药技术有限公司

Raffles PharmaTech Pte Ltd